Boston Scien Cp Stock Price, News & Analysis

Boston Scientific Corporation (NYSE: BSX) will host a conference call on October 27, 2021, at 8:00 a.m. EDT to discuss its financial results for the third quarter ending September 30, 2021. The call will feature Mike Mahoney, CEO, and Dan Brennan, CFO, providing insights into the company's performance. A news release with the financial results will precede the call. Interested parties can access the live webcast and replay via investors.bostonscientific.com.

Boston Scientific (NYSE: BSX) announced an agreement to acquire Devoro Medical, developer of the WOLF Thrombectomy® Platform, for approximately $269 million and up to $67 million upon achieving certain milestones. This acquisition aims to enhance Boston Scientific's thrombectomy capabilities, complementing existing products like the EkoSonic™ Endovascular System. The deal is projected to be slightly dilutive to earnings in 2021 but is expected to have a neutral impact on adjusted EPS in 2022. The transaction is anticipated to close in Q4 2021.

Boston Scientific announced positive results from the EPOCH clinical trial for TheraSphere Y-90 Glass Microspheres in treating metastatic colorectal cancer (mCRC) of the liver. The trial met both primary endpoints of progression-free survival (PFS) and hepatic progression-free survival (hPFS). With 428 patients involved, the trial showed that TheraSphere treatment significantly improved PFS and hPFS compared to standard chemotherapy alone. This data will support future FDA submissions, potentially providing broader access to this therapy for mCRC patients.

Boston Scientific Corporation (BSX) will hold a hybrid investor meeting on September 22, 2021, from 8:30 a.m. to 12:30 p.m. EDT, to discuss its financial goals and growth strategies. The meeting will feature business unit overviews, updates on product pipelines, and highlights from key segments including Cardiovascular, MedSurg, and Rhythm and Neuro. Interested parties can register for the live event in Boston or join via webcast. A replay will be available for one year post-event.

Boston Scientific announced the completion of its acquisition of Lumenis Ltd.'s global surgical business for $1.07 billion, which is expected to generate approximately $200 million in revenue for 2021. This acquisition allows Boston Scientific to integrate Lumenis's advanced laser technology into its urology and otolaryngology offerings, enhancing its growth prospects in Europe and Asia. The deal is projected to be slightly dilutive in 2021, with earnings expected to become accretive in 2022 and beyond as synergies are realized and integration progresses.

Boston Scientific Corporation (NYSE: BSX) received FDA 510(k) clearance for its EXALT Model B Single-Use Bronchoscope, intended for bedside procedures in ICU and OR settings. The bronchoscope enhances suction performance and imaging quality, available in three sizes. With over 1.2 million annual procedures using bronchoscopes in the U.S., the single-use design mitigates infection risks associated with reusable devices. Limited market release is expected soon following the completion of CE marking in May 2021.

Boston Scientific has launched the HI-PEITHO clinical trial, investigating the efficacy of the EkoSonic Endovascular System combined with anticoagulation for treating acute, intermediate-high-risk pulmonary embolism (PE). The trial, enrolling up to 544 patients across 65 sites in the U.S. and Europe, aims to compare outcomes against anticoagulation alone. Nearly one million patients are impacted by PE annually in the U.S. and Europe, emphasizing the trial's significance. The study follows patients for a year to assess adverse events and improve clinical guidelines for PE treatment.

Boston Scientific (NYSE: BSX) received a New Technology Add-on Payment (NTAP) from the U.S. Centers for Medicare & Medicaid Services (CMS) for its EXALT™ Model D Single-Use Duodenoscope, effective October 1, 2021. This reimbursement will enhance access to this technology for Medicare patients, who constitute over 40% of ERCP procedures in the U.S. The duodenoscope aims to reduce infection risks associated with traditional reusable models, aligning with FDA recommendations for more disposable options.

Boston Scientific Corporation (BSX) reported second quarter 2021 net sales of $3.077 billion, a 53.6% year-over-year increase. GAAP net income reached $172 million or $0.12 per share, recovering from a loss of $153 million last year. Adjusted EPS soared to $0.40, beating expectations. Growth was driven by strong sales across segments: MedSurg (64.6%), Rhythm and Neuro (65.0%), and Cardiovascular (51.4%). The company also initiated European launches for new medical devices and expanded its electrophysiology portfolio.